- Company
- Ilaris’s reimbursement imminent in Korea
- by Eo, Yun-Ho Jul 1, 2024 05:47am
- The ultra-rare disease treatment Ilaris has finally passed the final hurdle to its reimbursement in Korea. Novartis Korea recently completed drug price negotiations with the National Health Insurance Service for Ilaris (canakinumab), a treatment for hereditary periodic fever syndrome. The company was quick to accept the conditional ben
- Company
- GC Cell-Artiva-MSD’s 'CAR-NK' co-R&D deal terminated
- by Kim, Jin-Gu Jun 28, 2024 04:33am
- GC Cell and Artiva Biotherapeutic’s collaborative research and development (R&D) agreement with MSD for ‘CAR-NK solid tumor treatment’ has been terminated. MSD informed Artiva Biotherapeutic, GC Cell’s U.S. subsidiary, of the contract termination. As a result, Artiva Biotherapeutic and GC Cell’s research agreement has been automatic
- Company
- KOD will service platform for epilepsy patients next year
- by Lee, Tak-Sun Jun 28, 2024 04:33am
- A platform for epilepsy patients and healthcare professionals will soon be launched in Korea. Japan's Knock on the Door (KOD) announced in May that it has established its branch in Seoul and is preparing to launch the service next year. KOD was established in Tokyo, Japan, in 2018 with the goal of "Realizing a society where patients
- Company
- MSD seeks to expand NIP subjects for Gardasil
- by Hwang, Byung-woo Jun 28, 2024 04:33am
- With the aim of expanding coverage of its human papillomavirus (HPV) vaccine within the National Immunization Program (NIP), MSD Korea has been working to improve its vaccine awareness. Expanding NIP coverage of the HPV vaccine is one of the hot topics on the government's agenda. In fact, it was ranked the third-most important task in the 'Es
- Company
- Spinraza tops Q1 revenue in SMA mkt with KRW 17.7 billion
- by Nho, Byung Chul Jun 28, 2024 04:32am
- Biogen Korea's Spinraza remains the No. 1 drug for spinal muscular atrophy (SMA) in the KRW 80 billion market. However, its performance has been somewhat sluggish due to the launch of competitors such as Roche Korea’s Evrysdi and Novartis’s Zolgensma. In terms of drug distribution performance, Spinraza's sales in Q1 of this year were
- Company
- 'Increased' competitiveness in autoimmune diseases
- by Son, Hyung-Min Jun 27, 2024 05:47am
- The Korean biopharmaceutical industry is successfully signing license agreements of drugs for autoimmune diseases. HK inno. N, IMBiologics, and Y-Biologics have signed license agreements for their jointly developed novel drug candidates. AprilBio has also signed a license agreement for a novel drug candidate that has shown efficacy in a phase 1
- Company
- New drug 'Mylotarg' for AML makes another attempt at reimb
- by Eo, Yun-Ho Jun 27, 2024 05:47am
- A new drug 'Mylotarg' for the treatment of acute myeloid leukemia (AML) is making another attempt to obtain insurance reimbursement listing. According to industry sources, Pfizer Korea has recently reapplied for reimbursement review for Mylotarg (gemtuzumab ozogamicin), a treatment for acute myeloid leukemia (AML). In May 2022, Mylota
- Company
- SGLT-2 diabetes drug Jardiance outsells mkt leader Forxiga
- by Nho, Byung Chul Jun 26, 2024 05:47am
- Boehringer Ingelheim's Jardiance and AstraZeneca's Forxiga are striving for mastery of the KRW 110 billion SGLT-2 inhibitor class single-agent diabetes drug market in Korea. In the first quarter of this year, Jardiance and Forxiga generated sales in the range of KRW 11.1 billion and KRW 8.0 billion, respectively. Notably, this is a reve
- Company
- Another anticancer drug 'Augtyro' set to be launched in KOR
- by Eo, Yun-Ho Jun 26, 2024 05:46am
- A ROS-1 targeting lung cancer treatment called 'Augtyro' is entering the Korean market. According to the industry sources, Bristol Myers Squibb (BMS) Korea has recently applied for market approval from the Ministry of Food and Drug Safety (MFDS) for its Augtyro (repotrectinib), an anticancer drug effective regardless of cancer types. T
- Company
- Returned license-outs for new drugs one after another
- by Kim, Jin-Gu Jun 26, 2024 05:46am
- Korean biopharmaceutical companies have been receiving termination notifications from their partnering companies for their licensed-out new drug candidates one after another. Olix Pharmaceuticals and Curacle recently received notifications of contract terminations from France’s Thea Open Innovation. Voronoi’s license-out agreement for
